10045Background: Comorbidities including dyslipidemia, diabetes and coronary heart disease are frequently found in elderly patients with advanced non-small cell lung cancer (NSCLC). Taking statin and/or metformin attenuates chronic inflammations, and could affect cancer outcomes. We aimed to evaluate prognostic impact of taking statin and/or metformin on survival in elderly patients with advanced NSCLC. Methods: Patients ≥ 70 years with advanced NSCLC incident from 2007 to 2012 were identified using reimbursement claims from Korea’s National Health Insurance Service Database, and exposures to statin and/or metformin were also documented. Cox proportional-hazards model and propensity score matched analysis were used to estimate the impact of drug exposures on overall survival (OS). Results: Excluding 976 treated by upfront anti-EGFR, 7298 receiving palliative chemotherapy were included: statin preparations were taken in 13.0%, metformin preparations in 13.8%, both in 3.5%, and neither in 76.6%, respectivel...